**Home**

**Gastrointestinal Cancer**

- **Colorectal cancer**
  - Adenocarcinoma of the rectum
  - MET amplified adenocarcinoma of the colon/rectum
  - Metastatic colorectal cancer, not otherwise stated

- **Gastroesophageal cancer**
  - Gastric and gastroesophageal junction adenocarcinoma

- **Liver and hepatobiliary cancer**
  - Cholangiocarcinoma
  - Cholangiocarcinoma/gallbladder carcinoma
  - Mesothelin-positive advanced pancreatic adenocarcinoma
  - Pancreatic ductal adenocarcinoma
  - Locally advanced, pancreatic adenocarcinoma

- **Anal cancer**
  - Squamous cell carcinoma of the anus

- **Neuroendocrine Tumors**
  - Gastroenteropancreatic Neuroendocrine Tumors

---

**ETCTN Trials by Disease/Treatment Area: Gastrointestinal Cancer**

- **10058**: A Phase I Study of Talimogene Laherparepvec (TALIMogene LAHERparepvec) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum
- **10181**: A Phase II Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer
- **9676**: A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase, pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)
- **10066**: A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
- **10211**: A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
- **10222**: Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) - Mutant Solid Tumors (2 cohorts: cholangiocarcinoma and other solid tumors)
- **10129**: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (3 cohorts: glioma, cholangiocarcinoma, and other solid tumors)
- **10276**: A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (Phase 1: advanced/metastatic solid tumors; Phase 2: advanced/metastatic hepatobiliary tumors)
- **10208**: A Phase III study of Axitumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
- **9881**: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, and SCLC)
- **10366**: A Phase 1/2 Study of M3814 in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
- **9673**: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
- **10388**: A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

**NOTE**: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 16, 2019